In a landmark in paediatric oncology research, children with high-risk neuroblastoma across Europe and North America will be treated together for the first time. Read more
Grant Award - High-Risk Neuroblastoma Clinical Trial 2 Read more
Solving Kids’ Cancer Europe, Solving Kids' Cancer in New York, Oscar Knox Fund and Merryn Lacy Trust have awarded a grant of $420,000 to co-investigators. Read more
This exciting new clinical trial sees 17 transatlantic centres in the UK, USA and Europe, recruiting patients simultaneously for an innovative new third-generation ALK-inhibitor agent lorlatinib (PF-06463922). Read more
The National Neuroblastoma Genetics Reference Centre aims to provide a comprehensive service genetic characterisation of all neuroblastoma tumours at diagnosis and a subset at relapse. Read more
In this study, blood and bone marrow samples from 120 children treated in the BEACON-Neuroblastoma trial will be collected in order to analyse levels of neuroblastoma mRNAs Read more
MiNivAn aims to improve the cure rate of children with relapsed or refractory neuroblastoma by combining targeted radiotherapy (I-131 MIBG) with the antibodies anti-GD2 (ch14.18/CHO) and anti-PD1 (nivolumab). Read more
Solving Kids’ Cancer funds a dedicated Senior Trials Coordinator for Neuroblastoma within the Children’s Cancer Trials Team (CCTU) of the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham. Read more
Bringing together American NCI PPTC and European ITCC-P4 paediatric preclinical research consortiums together for the first time ever via the Pediatric Cancer Working Group at the AACR Annual Meeting. Read more
The BEACON study is a chemotherapy and antibody combination trial. Read more
Solving Kids’ Cancer is leading an international competitive funding call commencing with a Request for Applications (RFA) Read more
Solving Kids’ Cancer has issued a joint 2019 International Challenge Grant Call for GBP 500,000 awarded over three years Read more